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Introduction. Despite modern radiological workup, surgeons can still be surprised by intraoperative findings or by the pathologist’s
report.Materials &Methods.We describe the case of a 52-year-oldmalewhowas referred to our clinic with a single sided conductive
hearing loss. He ultimately underwent middle ear exploration and excision of a middle ear tumour followed by second look and
ossiculoplasty a year later. Results. Though preoperative CT and MRI scanning were suggestive of a congenital cholesteatoma, the
pathologist’s report diagnosed a middle ear adenoma. Discussion. Middle ear glandular tumors are extremely rare and, despite
numerous histological techniques, continue to defy satisfactory classification. Most surgeons advocate surgical excision though
evidence of the tumour’s natural course and risk of recurrence is lacking.
1. Introduction
Middle ear glandular tumors are extremely rare and, despite
numerous histological techniques, continue to defy satisfac-
tory classification. Their cell line of origin, natural history,
and progression if left untreated are unknown. Patients gener-
ally present with conductive hearing loss and most surgeons
advocate surgical excision with or without immediate or
delayed reconstruction of hearing.
2. Case Report
A 52-year-old patient was referred by a private ENT doctor to
the University Hospital Zurich on suspicion of a right sided
cholesteatoma. The patient described a loss of hearing and
pressure sensation in the right ear which had been present
for two months. The patient reported no pain, otorrhoea,
dizziness, or systemic signs of infection. Past medical history
was unremarkable. The patient took no medications and had
no allergies.
Otoscopy showed an intact eardrum but with the sug-
gestion of white mass behind the eardrum in the poste-
rior superior/inferior quadrants. A pure tone audiogram
(Figure 1) showed normal hearing in the right ear, with a
high frequency sensorineural loss in the left. Temporal bone
computer tomography showed a right sided middle ear soft
tissue mass with possible erosion of the ossicles (Figure 2). A
working diagnosis of a congenital cholesteatoma was made,
and the patient was sent for MRI.
TheMRI showed a 6 × 10mm soft tissue mass, isointense
on T1 and T2 sequences, with inhomogeneous gadolinium
contrast uptake in the meso- and hypotympanum. Posterior
to this was a 5mm lesion, hyperintense signal on T2, without
contrast uptake and without reduced apparent diffusion
coefficient. All the inner ear structures were intact. These
findings were felt to bemore consistent with a glomus tumour
than a cholesteatoma and the second lesion was felt to be
artifact from a shine-through effect from mucosal swelling.
The patient underwent an explorative mastoidectomy,
epitympanectomy, and tympanoplasty.
Intraoperatively (Figure 3), the whole middle ear was
filled with the soft tissue mass apart from a small area superi-
orly/anteriorly.The chorda tympani had to be sacrificed along
with an epitympanectomy to allow adequate visualization and
excision of the mass.
Pathological examination revealed a glandular and neu-
roendocrine tumorwith areas of pleomorphic nuclei (Figures
4(a) and 4(b)). Immunohistochemically, the cells exces-
sively expressed a marker protein for neuroendocrine cells
(synaptophysin, Figure 4(c)) and partially chromogranin A.
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Figure 1: (a) Pure tone audiogram at presentation. (b) Pure tone audiogram 2 years following PORP.
Figure 2: Computer tomogram at presentation.
Figure 3: Intraoperative findings.
The proliferation rate was determined to be less than 1%.
The diagnosis of a neuroendocrine differentiated middle ear
adenoma was made, but the pathologist emphasized the need
to rule out the possibility that this was a metastasis of an as
yet unidentified primary.
A postoperative MRI scan performed 3 months later
showed a discrete mucosal swelling in the hypotympa-
num with contrast uptake, possibly consistent with residual
tumour. A further MRI scan 6 months later showed regres-
sion of this finding.
A full year after the initial excision, a second look was
performed. No signs of persistence or recurrence were found,
and a partial ossicular reconstruction prosthesis (PORP) was
performed with good results (see Figure 1(b)).
3. Discussion
Middle ear glandular neoplasms are rare tumours thought
to arise from the epithelial lining of the middle ear or a
stromal precursor derived from the neural crest [1]. MEAs
were first described by Hyams and Michaels in 1976 [1]
and controversy exists as to what extent they represent a
different entity from carcinoid tumours of themiddle ear first
described by Murphy et al. in 1980 [2]. Murphy felt that his
case was better described as a carcinoid tumour because of
ultrastructural evidence of a neuroendocrine differentiation.
With only 94 published cases [3], current opinion leans
towards classifying all these tumours as MEAs with a subset
of neuroendocrine variants [4], as this appropriately implies
their benign behavior. Some authors however argue that
the appropriate terminology would be adenocarcinoid or
amphicrine tumor in order to reflect its dual nature [5].
MEAs are grossly vascular tumors which are well cir-
cumscribed despite having no capsule. The most common
presenting symptom is conductive hearing loss, though
otalgia or a sensation of aural fullness is also commonly
described. The mass tends to surround the ossicles without
erosion, though in 8 other case reports, as with our case, bony
erosion has been described. Facial paresis [4, 6] due to either
compression or frank invasion [7] has also been reported.
Only one case report describes a carcinoid syndrome with
an MEA [8]. Middle ear carcinoid metastatic potential has
also been described leading some to conclude that it should
be considered a low-grade malignancy [7, 9, 10].
In 2009, Saliba and Evrard performed a thorough anal-
ysis of the literature and proposed a 3-tier classification
according to immunohistochemistry (+/−) and metastasis
(+/−). When both are negative, the tumor is described as
an MEA. The most common type however shows positive
immunohistochemistry and no metastasis and is described
as a neuroendocrine adenoma of the middle ear. The rarest
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Figure 4: (a) Histological finding (overview), neuroendocrine adenoma (hematoxylin-eosin stain). (b) Histological finding (magnification),
neuroendocrine adenoma (hematoxylin-eosin stain). (c)Histological finding (magnification), neuroendocrine differentiation (synaptophysin
stain).
finding is of a tumor with both positive immunohistochem-
istry and metastasis/carcinoid syndrome and is described
as a carcinoid tumor of the middle ear [3]. Of note, this
paper mentions an average disease free interval of 53 months,
but it is not clear how many patients had aggressive initial
treatment, or indeed, how many actually had recurrence.
Pathologically MEAs are composed of exocrine and
neuroendocrine cell types, sometimes with neuropeptides
such as chromogranin, synaptophysin, serotonin, and pan-
creatic polypeptide [11]. They are predominantly composed
of cuboidal-to-columnar cells with indistinct cytoplasmic
borders. The nuclei tend to be round to oval with minimal
pleomorphism [12]. The chromatin often shows a “salt and
pepper” pattern consistent with neuroendocrine origin.
Treatment is surgical excisionwith orwithout the ossicles.
Local recurrences rates as high as 12.7% are reported [3] and
require the repeat of the operation. Adjuvant radiotherapy
or chemotherapy as used for pulmonary or gastrointestinal
carcinoid, even when the labyrinth is nonfunctioning, is
discouraged [6].
4. Conclusions
Middle ear glandular neoplasms are rare tumors of the
middle ear. Controversy still exists as to the most appropriate
description and classification of these tumors and whether
they should be subclassified in order to aid treatment and
prognostication. Clinical suspicion of such a tumormandates
a thorough radiological workup, and patient fitness/consent
aside, operative excision. This should be aggressive in order
to keep down local recurrence rates and simultaneous or
delayed reconstruction of the hearing may then be per-
formed. Long term followup is recommended to rule out late
recurrence and metastatic disease.
5. Summary
(i) Preoperative radiological workup does not always
correlate with intraoperative findings or with the
ultimate diagnosis. Clinicians should keep an open
mind and be prepared to change their operative plan
according to intraoperative findings.
(ii) Middle ear glandular neoplasms are rare and contro-
versy exists as to their appropriate classification.
(iii) Currently, the classification by Saliba et al. is the most
widespread and includes (in order of prevalence)
neuroendocrine adenomas, adenomas, and carcinoid
tumours according to immunohistochemicalmarkers
and metastasis.
(iv) Adjuvant radiotherapy of chemotherapy is not rec-
ommended. Instead, a surgical second look can be
performed, especially if interval imaging is suggestive
of persistent disease.
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